Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 81 fludarabine phosphate 77 Peripheral Blood Stem Cell Transplantation 62 Mycophenolic Acid 55 Tacrolimus 54 Whole-Body Irradiation 52 Busulfan 51 Antilymphocyte Serum 45 Cyclosporine 41 fludarabine 36 Methotrexate 32 Filgrastim 32 Melphalan 30 Radiotherapy 25 Methylprednisolone 19 Cytarabine 17 Cord Blood Stem Cell Transplantation 17 Sirolimus 15 Azacitidine 15 Granulocyte Colony-Stimulating Factor 14 Alemtuzumab 14 thymoglobulin 13 Flow Cytometry 13 Etoposide 13 Cyclosporins 13 Specimen Handling 10 Biopsy 10 Thiotepa 9 Psychiatric Rehabilitation 9 Decitabine 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Myeloproliferative Disorders × Hydroxyzine × Clear all

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡